The role of IL-6 and PD-L1 in occurrence of Gastroesophageal reflux disease

doi:10.3877/cma.j.issn.2095-8765.2020.03.002

Abstract

Abstract:

Objective

To investigate the role of Interleukin-6 (IL-6) and Programmed Death Ligand 1 (PD-L1) in the pathogenesis of Gastroesophageal reflux disease (GERD).

Methods

In vitro, culture rat esophageal epithelial cells and CD4⁺T cells and establish a coculture system with normal rat esophageal epithelial cells and CD4⁺T cells. In the experimental group, chenodeoxycholic acid, pancreatin, and hydrochloric acid were added to the culture medium in order to adjust the pH of the medium to 4, 5, and 6, respectively; cells were cultured for 12 h, 24 h, and 48 h. The control group cells were cultured normally without any stimulation. ELISA and Western blot were used to detect the expression levels of IL-6 and PD-L1 in each group. The experimental data is expressed as

x ˉ

±s. The overall comparison uses repeated measures analysis of variance, and no correction is required to meet the sphericity test If correction is required, Green house-Geisser correction is used.

Results

With the increase of pH concentration and the extension of culture time, the expression levels of IL-6 and PD-L1 in each group were significantly increased (P＜0.05); expression levels of IL-6 and PD-L1 in epithelial cells and CD4⁺ cell co-culture system were reached the highest level (P＜0.05).

Conclusion

The inflammatory cytokine IL-6 may promote the expression of PD-L1 in GERD and play an important role in the occurrence and development of GERD.

Key words: Gastroesophageal reflux disease, Interleukin-6, programmed death ligand 1

Aliyeguli·Aipire, Maimaiti·Yisireyili, Yeledan·Mahan, Kelimu·Abudureyimu. The role of IL-6 and PD-L1 in occurrence of Gastroesophageal reflux disease[J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2020, 07(03): 144-149.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwsgflbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8765.2020.03.002

https://zhwsgflbdzzz.cma-cmc.com.cn/EN/Y2020/V07/I03/144

Figures/Tables 7

References 15

1	克力木·阿不都热依木，张成，汪忠稿．胃食管反流病与食管裂孔疝外科临床研究现状与争议［J/CD］.中华胃食管反流病电子杂志，2014，1(1)：4-6.
2	Dunbar KB, Agoston AT, Odze RD, et al. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes [J]. Jama, 2016, 315(19)：2104-2112.
3	Delaney BC. Review article: Prevalence and epidemiology of gastroeso Phageal reflux disease[J]. Aliment Pharmacol Ther, 2004, 20 Suppl 8：2-4.
4	吾布力卡斯木·吾拉木，巴突尔·艾克木，买买提·依斯热依力，等. 不同亚型胃食管反流病食管黏膜下层炎症因子变化特点研究［J/CD］.中华胃食管反流病电子杂志，2018，5(3)：97-101.
5	Kanazawa Y, Isomoto H, Wen CY, et al. Impact of endoscopically minimal involvement on IL-8 mRNA expression in esophageal mucosa of patients with non-erosive reflux disease. [J]. World J Gastroenterol.2003 D, 9(12)：2801-2804.
6	屈坤鹏, 成晓舟. 我国部分地区胃食管反流病患病率的Meta分析[J/CD]. 中华胃食管反流病电子杂志, 2015（1）：34-44.
7	梁国强. 胃食管反流病的病因分析及其发病机制研究[J]. 现代养生, 2014(10)：70-70.
8	Sihvo EI, Salminen JT, Rantanen TK, et al. Oxidative stress has a role in malignant transformation in Barrett's oesophagus[J]. Int J Cancer, 2002, 102(6)：551-555.
9	Dvorak K, Payne CM, Chavarria M, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus[J]. Gut, 2007, 56(6)：763-771.
10	田燕，陈吉.炎症介质与胃食管反流病发病机制的研究进展[J]. 疾病监测与控制杂志, 2016(1)：573,571.
11	Wulamu W, Yisireyili M, Aili A, et al. Chronic stress augments esophageal inflammation, and alters the expression of transient receptor potential vanilloid 1 and protease-activated receptor 2 in a murine model[J]. Mol Med Rep, 2019, 19(6)：5386-5396.
12	Derks S, Katie S, Liao X, et al. Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma[J]. Cancer Immunol Res, 2015, 3(10)：1123-1109.
13	Wolfle S J, Strebovsky J, Bartz H, et al. PD-L1 expression on tolerogenic APCs is controlled bySTAT-3[J]. Eur J Immunol, 2011, 41(2)：413-424.
14	Loos M, Langer R, Schuster T, et al. Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma[J]. Ann Thorac Surg, 2019, 1(4)：1025-1031.
15	Ribas A. Tumor immunotherapy directed at PD-1[J]. N Engl J Med, 2012, 366(26)：2517-2519.

分组		T=12	T=24	T=48
食管上皮细胞组	pH=4	27.23±0.07	36.00±0.04	41.28±0.45
	pH=5	19.15±0.05	32.41±0.21	38.18±0.01
	pH=6	12.29±0.29	16.26±0.26	19.43±0.23
	未处理		5.89±016
CD4⁺T细胞组	pH=4	62.95±0.95	126.74±0.25	131.22±0.22
	pH=5	54.18±1.18	113.93±0.43	125.0±0.07
	pH=6	40.02±1.02	97.62±0.62	107.4±0.45
	未处理		15.08±0.26
食管上皮细胞+ CD4⁺T细胞共培组	pH=4	66.35±0.35	136.11±0.11	137.00±0.18
	pH=5	59.53±0.53	127.02±0.32	132.43±0.99
	pH=6	46.57±0.27	108.93±0.47	120.00±0.20
	未处理		18.92±0.23

分组		T=12	T=24	T=48
食管上皮细胞组	pH=4	27.23±0.07	36.00±0.04	41.28±0.45
	pH=5	19.15±0.05	32.41±0.21	38.18±0.01
	pH=6	12.29±0.29	16.26±0.26	19.43±0.23
	未处理		5.89±016
CD4⁺T细胞组	pH=4	62.95±0.95	126.74±0.25	131.22±0.22
	pH=5	54.18±1.18	113.93±0.43	125.0±0.07
	pH=6	40.02±1.02	97.62±0.62	107.4±0.45
	未处理		15.08±0.26
食管上皮细胞+ CD4⁺T细胞共培组	pH=4	66.35±0.35	136.11±0.11	137.00±0.18
	pH=5	59.53±0.53	127.02±0.32	132.43±0.99
	pH=6	46.57±0.27	108.93±0.47	120.00±0.20
	未处理		18.92±0.23

变异来源	SS	df	MS	F	P
时间	42646.42	2	21323.21	148260.24	＜0.05
时间*pH	141.88	4	35.47	246.62	＜0.05
时间*组	12643.38	4	3160.84	21977.34	＜0.05
时间pH组	112.67	8	14.08	97.93	＜0.05
重复测量误差	5.18	36	0.14

变异来源	SS	df	MS	F	P
时间	42646.42	2	21323.21	148260.24	＜0.05
时间*pH	141.88	4	35.47	246.62	＜0.05
时间*组	12643.38	4	3160.84	21977.34	＜0.05
时间pH组	112.67	8	14.08	97.93	＜0.05
重复测量误差	5.18	36	0.14

分组		T=12	T=24	T=48
食管上皮细胞组	pH=4	0.237±0.006	0.289±0.010	0.358±0.010
	pH=5	0.132±0.007	0.171±0.010	0.410±0.010
	pH=6	0.092±0.001	0.136±0.001	0.255±0.001
	未处理		0.093±0.003
CD4⁺T细胞组	pH=4	0.223±0.001	0.311±0.009	0.387±0.002
	pH=5	0.139±0.001	0.152±0.001	0.386±0.002
	pH=6	0.093±0.006	0.130±0.001	0.234±0.001
	未处理		0.099±0.002
食管上皮细胞+CD4⁺T细胞共培组	pH=4	0.289±0.001	0.472±0.001	0.601±0.001
	pH=5	0.187±0.059	0.321±0.020	0.600±0.001
	pH=6	0.162±0.001	0.275±0.003	0.423±0.002
	未处理		0.259±0.002

Please choose a citation manager

Content to export